Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Gigaphoton Excimer Laser for Advanced Packaging Installed at Japanese Company

Today 19:00 EST

From Gigaphoton Inc.

Via Business Wire

Sustainability Focus Session 2025

Today 18:15 EST

From Woodside Energy Group

Via Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Today 18:00 EST

From BeOne Medicines Ltd.

Via Business Wire

National Fuel Gas Company Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – NFG

Today 17:49 EST

From DJS Law Group

Via Business Wire

Gartner Announces Gartner Finance Symposium/Xpo 2026 in Sydney

Today 17:00 EST

From Gartner

Via Business Wire

Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Today 15:12 EST

From Halper Sadeh LLC

Via Business Wire

Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Today 14:49 EST

From Halper Sadeh LLC

Via Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

Today 11:00 EST

From AOP Health

Via Business Wire

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Today 9:30 EST

From Incyte

Via Business Wire

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Today 9:30 EST

From Incyte

Via Business Wire

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Today 8:00 EST

From Gilead Sciences, Inc.

Via Business Wire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Today 7:50 EST

From Genmab A/S

Via Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future

Today 7:00 EST

From CoMotion

Via Business Wire

Zai Lab Announces Updates to China’s National Reimbursement Drug List

Today 0:11 EST

From Zai Lab Limited

Via Business Wire

Memphis Shines as Thousands Unite for St. Jude Memphis Marathon Weekend

December 06, 2025

From St. Jude Children’s Research Hospital

Via Business Wire

Rosen Law Firm Encourages Klarna Group plc Investors to Inquire About Securities Class Action Investigation – KLAR

December 06, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

December 06, 2025

From Pfizer Inc.

Via Business Wire

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

December 06, 2025

From Star Therapeutics

Via Business Wire

TheOther Debuts Premium Matcha at an Intimate Art Basel Celebration in Miami Co-Hosted By Central Cee

December 06, 2025

From TheOther

Via Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

December 06, 2025

From Arcellx, Inc.

Via Business Wire

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 06, 2025

From Gilead Sciences, Inc.

Via Business Wire

Worthington Steel Issues Statement Regarding Klöckner & Co SE

December 06, 2025

From Worthington Steel, Inc.

Via Business Wire

Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting

December 06, 2025

From Orca Bio

Via Business Wire

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

December 06, 2025

From Genmab A/S

Via Business Wire

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

December 06, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Deciphera Pharmaceuticals Inc.

Via Business Wire

NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025

December 06, 2025

From NMDP

Via Business Wire

ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual Meeting

December 06, 2025

From ReAlta Life Sciences, Inc.

Via Business Wire

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation

December 06, 2025

From Genetix Biotherapeutics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.